Bilessglu Chiglitazar Sodium Tablets

1. Indications and Usage
Glycemic and Lipid Control: Indicated as an adjunct to diet and exercise to improve glycemic control and lipid metabolism in adults with type 2 diabetes mellitus, particularly those with concomitant dyslipidemia.
Therapeutic Context: Can be used as monotherapy or in combination with metformin.
2. Dosage and Administration
Starting Dose: The recommended starting dose is 4 mg once daily, taken orally with or without regard to meals.
Titration: If glycemic and lipid control is inadequate, the dose may be increased to 8 mg once daily after clinical assessment.
Renal/Hepatic Adjustment: For patients with severe renal impairment (including those on dialysis), the dose should be limited to 4 mg once daily. Use is not recommended in patients with severe hepatic impairment (Child-Pugh C).
Missed Dose: If a dose is missed, it should be taken as soon as remembered. If it is close to the next dose, skip the missed dose.
3. Mechanism of Action
PPARα,γ Agonism: Chiglitazar is a selective agonist of peroxisome proliferator-activated receptors α (PPARα) and γ (PPARγ).
Dual Effect: Activation of PPARγ enhances insulin sensitivity in peripheral tissues (muscle and adipose), while activation of PPARα improves lipid metabolism by reducing triglycerides and increasing HDL cholesterol.
4. Safety and Warnings
Heart Failure: PPARγ agonists (thiazolidinediones) are associated with fluid retention and an increased risk of heart failure. Patients should be monitored for signs of heart failure.
Hepatic Enzyme Elevation: Elevations in liver enzymes (ALT, AST) have been reported. Liver function should be monitored periodically.
Bone Fractures: Increased risk of bone fractures, particularly in women, has been observed with this class of drugs.
Macular Edema: Cases of diabetic macular edema have been reported.
5. Adverse Reactions and Clinical Research
Common Adverse Reactions: Hypoglycemia (especially with insulin/sulfonylureas), hyperlipidemia, headache, and edema.
Hypoglycemia: Low risk as monotherapy, but the risk increases when used with insulin or sulfonylureas.
Other Adverse Effects: Weight gain, upper respiratory tract infection, and back pain have been reported.
Clinical Findings: Clinical trials have demonstrated significant reductions in HbA1c and triglycerides, with a concomitant increase in HDL cholesterol.
6. Drug Interations
CYP Enzymes: Chiglitazar is metabolized by CYP enzymes. Concomitant use with strong CYP inducers (e.g., rifampin) may reduce its efficacy, while strong inhibitors may increase exposure.
Hypoglycemic Agents: Concomitant use with insulin or sulfonylureas increases the risk of hypoglycemia.
Statins: No clinically significant interaction with statins has been observed, but monitoring for myopathy is advised.
7. Pharmaceutical Information
Active Ingredient: Chiglitazar Sodium.
Strengths: Typically available as 4 mg and 8 mg tablets.
Appearance: Film-coated tablets.
Storage: Store in a tightly closed container, protected from moisture and light, at controlled room temperature.